Search

Your search keyword '"Hedvat, Michael"' showing total 38 results

Search Constraints

Start Over You searched for: Author "Hedvat, Michael" Remove constraint Author: "Hedvat, Michael"
38 results on '"Hedvat, Michael"'

Search Results

1. Abstract 2983: Tumor-specific CD28 costimulatory bispecific antibodies enhance T cell activation in solid tumors

2. Supplementary Figure 3 from Antiangiogenic and Antimetastatic Activity of JAK Inhibitor AZD1480

3. Supplementary Figure 4 from Antiangiogenic and Antimetastatic Activity of JAK Inhibitor AZD1480

4. Data from Antiangiogenic and Antimetastatic Activity of JAK Inhibitor AZD1480

5. Supplementary Figure 2 from Antiangiogenic and Antimetastatic Activity of JAK Inhibitor AZD1480

6. Supplementary Figure 1 from Antiangiogenic and Antimetastatic Activity of JAK Inhibitor AZD1480

7. Supplementary Methods from Antiangiogenic and Antimetastatic Activity of JAK Inhibitor AZD1480

8. 1073 Costimulatory CD28 trispecific antibodies targeting PDL1 and PDL2 enhance T cell activation in solid tumors

10. 698 PD-L1 targeted CD28 costimulatory bispecific antibodies enhance T cell activation in solid tumors

11. The JAK2 Inhibitor AZD1480 Potently Blocks Stat3 Signaling and Oncogenesis in Solid Tumors

12. Abstract 1880: PDL1-targeted CD28 costimulatory bispecific antibodies enhance T cell activation in solid tumors

13. 697 Tumor-targeted CD28 costimulatory bispecific antibodies enhance T cell activation in solid tumors

14. Abstract 5654: Affinity tuned Xmab®2+1 anti-mesothelin x anti-CD3 bispecific antibody induces selective T cell-dependent cellular cytotoxicity of human ovarian cancer cells

15. Abstract 5663: Affinity tuned XmAb®2+1 PSMA x CD3 bispecific antibodies demonstrate selective activity in prostate cancer models

17. Abstract 2784: Simultaneous checkpoint-checkpoint or checkpoint-costimulatory receptor targeting with bispecific antibodies promotes enhanced human T cell activation

18. Abstract 1639: Combination of PD1 blockade and T cell costimulation by bispecific antibodies promotes human T cell activation and proliferation

19. Bortezomib induces apoptosis and growth suppression in human medulloblastoma cells, associated with inhibition of AKT and NF-ĸB signaling, and synergizes with an ERK inhibitor

20. Sorafenib inhibits STAT3 signaling associated with growth arrest and apoptosis of medulloblastomas

21. Selected Approaches for Rational Drug Design and High Throughput Screening to Identify Anti-Cancer Molecules

22. Endoplasmic reticulum protein BI-1 regulates Ca2+-mediated bioenergetics to promote autophagy

23. Enhanced delivery of mda-7/IL-24 using a serotype chimeric adenovirus (Ad.5/3) in combination with the apogossypol derivative BI-97C1 (Sabutoclax) improves therapeutic efficacy in low CAR colorectal cancer cells

24. Antiangiogenic and Antimetastatic Activity of JAK Inhibitor AZD1480

25. Targeting Mcl-1 for the therapy of cancer

26. Role of Excitatory Amino Acid Transporter-2 (EAAT2) and glutamate in neurodegeneration: Opportunities for developing novel therapeutics

27. Alkylation of Cysteine 468 in Stat3 Defines a Novel Site for Therapeutic Development

31. Sorafenib inhibits signal transducer and activator of transcription 3 signaling associated with growth arrest and apoptosis of medulloblastomas

32. 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one: National Harbor, MD, USA. 9-13 November 2016

34. 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one

35. Endoplasmic reticulum protein BI-1 regulates Ca2+- mediated bioenergetics to promote autophagy.

36. Antiangiogenic and Antimetastatic Activity of JAK Inhibitor AZD1480.

37. A B7-H3-targeted CD28 bispecific antibody enhances the activity of anti-PD1 and CD3 T-cell engager immunotherapies.

38. Bortezomib induces apoptosis and growth suppression in human medulloblastoma cells, associated with inhibition of AKT and NF-ĸB signaling, and synergizes with an ERK inhibitor.

Catalog

Books, media, physical & digital resources